NO20060871L - Azepinderivater som farmasoytiske midler - Google Patents

Azepinderivater som farmasoytiske midler

Info

Publication number
NO20060871L
NO20060871L NO20060871A NO20060871A NO20060871L NO 20060871 L NO20060871 L NO 20060871L NO 20060871 A NO20060871 A NO 20060871A NO 20060871 A NO20060871 A NO 20060871A NO 20060871 L NO20060871 L NO 20060871L
Authority
NO
Norway
Prior art keywords
pharmaceutical agents
azepine derivatives
receptors
activity
azepine
Prior art date
Application number
NO20060871A
Other languages
English (en)
Norwegian (no)
Inventor
Richard Martin
Tie-Lin Wang
Brenton Flatt
Xiao-Hui Gu
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of NO20060871L publication Critical patent/NO20060871L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20060871A 2003-07-23 2006-02-22 Azepinderivater som farmasoytiske midler NO20060871L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48985403P 2003-07-23 2003-07-23
PCT/US2004/023745 WO2005009387A2 (en) 2003-07-23 2004-07-23 Azepine derivatives as pharmaceutical agents

Publications (1)

Publication Number Publication Date
NO20060871L true NO20060871L (no) 2006-04-24

Family

ID=34102943

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060871A NO20060871L (no) 2003-07-23 2006-02-22 Azepinderivater som farmasoytiske midler

Country Status (14)

Country Link
US (1) US8466143B2 (enExample)
EP (1) EP1648408A4 (enExample)
JP (1) JP4679517B2 (enExample)
KR (1) KR20060052867A (enExample)
CN (1) CN1852748A (enExample)
AU (1) AU2004259009A1 (enExample)
BR (1) BRPI0412262A (enExample)
CA (1) CA2532798C (enExample)
CR (1) CR8258A (enExample)
EC (1) ECSP066392A (enExample)
IL (1) IL173287A0 (enExample)
NO (1) NO20060871L (enExample)
RU (1) RU2006105646A (enExample)
WO (1) WO2005009387A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
US7402680B2 (en) 2003-09-17 2008-07-22 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds
BRPI0608437A2 (pt) 2005-03-14 2009-12-29 Glaxo Group Ltd derivados tiazol fundidos que possuem afinidade para o receptor histamina h3
EP1963331A1 (en) * 2005-12-15 2008-09-03 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
US20080299118A1 (en) * 2007-06-01 2008-12-04 Wyeth FXR Agonists for the Treatment of Malignancies
US20080300235A1 (en) * 2007-06-01 2008-12-04 Wyeth FXR Agonists for Reducing LOX-1 Expression
US20090163474A1 (en) * 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
US20090215748A1 (en) * 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
BRPI0919948A2 (pt) 2008-10-31 2015-08-25 Madivation Technologies Inc Pirido[4,3-b]indois contendo porções rígidas
JP5551708B2 (ja) * 2008-10-31 2014-07-16 メディベイション テクノロジーズ， インコーポレイテッド アゼピノ［４，５−ｂ］インドール化合物およびその使用方法
CN101875627B (zh) * 2009-04-30 2014-01-15 凯惠科技发展(上海)有限公司 一种1-烷氧羰基-2h-异吲哚衍生物及其制备方法和中间体
EP2641907B1 (en) 2009-05-22 2015-01-28 AbbVie Inc. Preparation of modulators of 5-HT receptors
WO2011103433A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
US9193728B2 (en) 2010-02-18 2015-11-24 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US9040519B2 (en) 2010-02-18 2015-05-26 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
BR112012030534A2 (pt) * 2010-05-21 2015-09-29 Abbott Gmbh & Co Kg moduladores de receptores 5-ht e métodos de uso dos mesmos
WO2012112965A1 (en) * 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods of treating diabetes
EP2675459A4 (en) 2011-02-18 2014-08-06 Medivation Technologies Inc COMPOUNDS AND METHOD FOR THE TREATMENT OF DIABETES
WO2014031165A1 (en) * 2012-08-22 2014-02-27 Medivation Technologies, Inc. Compounds and methods of treating diabetes
SG11201703953WA (en) * 2014-11-21 2017-06-29 Akarna Therapeutics Ltd Fused bicyclic compounds for the treatment of disease
MX369623B (es) 2014-12-22 2019-11-14 Akarna Therapeutics Ltd Compuestos biciclicos fusionados para el tratamiento de enfermedades.
TWI698430B (zh) * 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
HK1249756A1 (zh) * 2015-03-26 2018-11-09 Akarna Therapeutics, Ltd. 用於治疗疾病的稠合双环化合物
WO2017143134A1 (en) * 2016-02-19 2017-08-24 Alios Biopharma, Inc. Fxr modulators and methods of their use
EP3463372A4 (en) * 2016-05-25 2019-11-13 Akarna Therapeutics, Ltd. CONDENSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES
BR112018073460A2 (pt) * 2016-05-25 2019-07-09 Akarna Therapeutics Ltd terapias combinadas usando moduladores do receptor farnesoide x (fxr)
CN111542319A (zh) * 2017-06-02 2020-08-14 阿卡纳治疗学有限公司 稠合的双环化合物
CN112312909B (zh) 2018-01-26 2024-07-02 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
US11673897B2 (en) 2018-01-26 2023-06-13 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR35044B (el) * 1966-05-10 1968-07-31 The Upjohn Company Μεθοδος παρασκευης οργανικων ενωσεων.
US4362739A (en) * 1981-05-04 1982-12-07 S.A. Omnichem Pyrrolo(2,3-d)carbazole derivatives, compositions and use
IL101851A (en) * 1991-06-13 1996-05-14 Janssen Pharmaceutica Nv 10-(4-piperidinyl- and piperidinylidene)-imidazo [1,2-a] (pyrrolo thieno or furano) [2,3] azepine derivatives their preparation and pharmaceutical compositions containing them and certain novel intermediates therefor
JPH09221475A (ja) * 1996-02-13 1997-08-26 Yamanouchi Pharmaceut Co Ltd 新規なオキシム誘導体
WO1999006410A1 (en) * 1997-08-04 1999-02-11 Amgen Inc. Hydroxamic acid substituted fused heterocyclic metalloproteinase inhibitors
AR024576A1 (es) 1999-06-18 2002-10-16 Univ Washington Composiciones y metodos para aumentar el flujo de salida de colesterol y aumentar la hdl usando la proteina abc1 transportadora del cassette que une elatp
FR2796070B1 (fr) * 1999-07-06 2003-02-21 Lipha Derives de benzodiazepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparation
MY122278A (en) * 1999-07-19 2006-04-29 Upjohn Co 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
US20020013334A1 (en) * 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
EP1963331A1 (en) * 2005-12-15 2008-09-03 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents

Also Published As

Publication number Publication date
IL173287A0 (en) 2006-06-11
CR8258A (es) 2006-08-30
BRPI0412262A (pt) 2006-09-19
US20070015746A1 (en) 2007-01-18
RU2006105646A (ru) 2007-09-10
KR20060052867A (ko) 2006-05-19
ECSP066392A (enExample) 2007-01-26
CN1852748A (zh) 2006-10-25
JP4679517B2 (ja) 2011-04-27
EP1648408A1 (en) 2006-04-26
CA2532798A1 (en) 2005-02-03
US8466143B2 (en) 2013-06-18
WO2005009387A2 (en) 2005-02-03
CA2532798C (en) 2013-02-19
JP2006528637A (ja) 2006-12-21
EP1648408A4 (en) 2006-11-29
AU2004259009A1 (en) 2005-02-03
WO2005009387A3 (en) 2006-03-02

Similar Documents

Publication Publication Date Title
NO20060871L (no) Azepinderivater som farmasoytiske midler
NO20061074L (no) Forbindelser og sammensetninger som inbibitorer av reseptortyrosinkinaseaktivitet
BRPI0513677B8 (pt) derivados de pirrol como agentes farmacêuticos
ATE547420T1 (de) Azepinoindol und pyridoindolderivate als pharmazeutische mittel
BRPI0417260A (pt) derivados de azepinoindol como agentes farmacêuticos
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
ECSP067043A (es) Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis
DE602004027936D1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
ATE469151T1 (de) Pyrrolopyridinderivate als proteinkinaseinhibitoren
CY1116463T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
NO20081975L (no) Diarylamin-inneholdende forbindelser og sammensetninger, og deres anvendelse som modulatorer av C-kit-reseptorer
TNSN05045A1 (en) Indole or benzimidazole derivatives for modulating ikappab kinase
NO20084489L (no) Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet
BR0310099A (pt) método para tratar dislipidemia ou uma doença associada com a dislipidemia
MY145074A (en) Thiazolidin-4-one derivatives
NO20082939L (no) Sykloheksyl piperasinyl metanon derivater og anvendelse av disse som histamin H3 reseptor modulatorer
DE60315479D1 (de) Pyrimidinamid derivate und deren verwendung
BRPI0413013A (pt) composto, seus sais, solvatos, e derivados farmaceuticamente funcionais, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou distúrbios, e de doenças
WO2006020680A3 (en) Heterocyclic compounds as pharmaceutical agents
WO2008021048A3 (en) Adp-ribosyltransferase based methods and compositions
NO20073702L (no) Ikke-steroid glukocorticoid reseptor modulatorer
CO5700723A2 (es) Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca
NO20075508L (no) Stannsoporfinpreparater og administrering
EA200602081A1 (ru) Пиридиновые производные алкилоксиндолов в качестве агентов, активных в отношении рецептора 5-нт7

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application